Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors.

Lai, Xiulan; Stiff, Andrew; Duggan, Megan; Wesolowski, Robert; Carson, William E; Friedman, Avner

Lai, Xiulan; Stiff, Andrew; Duggan, Megan; Wesolowski, Robert; Carson, William E; Friedman, Avner.

Afiliação

Lai X; Institute for Mathematical Sciences, Renmin University of China, 100872 Beijing, P. R. China.
Stiff A; Medical Scientist Training Program, The Ohio State University, Columbus, OH 43210.
Duggan M; Biomedical Sciences Graduate Program, The Ohio State University, Columbus, OH 43210.
Wesolowski R; Department of Surgery, The Ohio State University, Columbus, OH 43210.
Carson WE; Stefanie Spielman Comprehensive Breast Center, Wexner Medical Center, The Ohio State University, Columbus, OH 43212.
Friedman A; Division of Surgical Oncology, Department of Surgery, The Ohio State University, Columbus, OH 43210.

Proc Natl Acad Sci U S A ; 115(21): 5534-5539, 2018 05 22.

Article em En | MEDLINE | ID: mdl-29735668

Assuntos

Antineoplásicos/farmacologia; Antígeno B7-H1/antagonistas & inibidores; Neoplasias da Mama/tratamento farmacológico; Antígeno CTLA-4/antagonistas & inibidores; Modelos Teóricos; Proteínas/antagonistas & inibidores; Animais; Neoplasias da Mama/metabolismo; Neoplasias da Mama/patologia; Modelos Animais de Doenças; Quimioterapia Combinada; Feminino; Humanos; Camundongos

Palavras-chave

BET inhibitor; antiPD-L1; combination therapy; mathematical model

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Proteínas / Antígeno B7-H1 / Antígeno CTLA-4 / Modelos Teóricos / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Proc Natl Acad Sci U S A Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google